Cargando…

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

BACKGROUND: Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). To date, no blood biomarkers have been identified in NSCLC t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soyano, Aixa E., Dholaria, Bhagirathbhai, Marin-Acevedo, Julian A., Diehl, Nancy, Hodge, David, Luo, Yan, Manochakian, Rami, Chumsri, Saranya, Adjei, Alex, Knutson, Keith L., Lou, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251165/ https://www.ncbi.nlm.nih.gov/pubmed/30470260 http://dx.doi.org/10.1186/s40425-018-0447-2

Ejemplares similares

Next generation of immune checkpoint therapy in cancer: new developments and challenges
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Immunotherapies targeting stimulatory pathways and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Emerging therapeutic agents for lung cancer
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2016)

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer
por: Shi, Huashan, et al.
Publicado: (2021)

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
por: Majeed, Umair, et al.
Publicado: (2021)

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
por: Seegobin, Karan, et al.
Publicado: (2020)

Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer
por: Zhou, Kexun, et al.
Publicado: (2021)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Trends in participant race and sex reporting in lung cancer phase III clinical trials
por: Aslam, Faaiq N., et al.
Publicado: (2023)

Neuroendocrine Tumor Involving the Epicardium
por: Soyano, Aixa E., et al.
Publicado: (2017)

Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence
por: Soyano, Aixa E., et al.
Publicado: (2019)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
por: Majeed, Umair, et al.
Publicado: (2023)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
por: Li, Shenduo, et al.
Publicado: (2023)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Genomic landscape of lung adenocarcinomas in different races
por: Shi, Huashan, et al.
Publicado: (2022)

A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab
por: Sh Ahmed, Omar, et al.
Publicado: (2022)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)

Next generation of immune checkpoint inhibitors and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Emerging therapeutic agents for advanced non-small cell lung cancer
por: Chen, Ruqin, et al.
Publicado: (2020)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy
por: Sammons, Sarah, et al.
Publicado: (2022)

Antimicrobial de-escalation in patients with high-risk febrile neutropenia: Attitudes and practices of adult hospital care providers
por: Gorsline, Chelsea A., et al.
Publicado: (2021)

Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review
por: Wallace, Gerald, et al.
Publicado: (2023)

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
por: Bhatnagar, Bhavana, et al.
Publicado: (2014)

Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK‐positive non‐small‐cell lung cancer: Case report and review of the literature
por: Wiest, Nathaniel E., et al.
Publicado: (2021)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients
por: Chumsri, Saranya, et al.
Publicado: (2021)

Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients
por: Advani, Pooja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_roj6em4r00lb06mbra0c63h7ni